Overview

Study to Evaluate Safety, Tolerability and PK of C-10355 and C-10358 in Healthy Subjects

Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
This two-part study will assess, in healthy volunteers, under both fasted and fed conditions, and in a sequential manner, the safety, tolerability and pharmacokinetics (PK) profile of single doses of C-10355 and C-10358 and single ascending doses of the selected compound compared to a single dose of Kalydeco®.
Phase:
Phase 1
Details
Lead Sponsor:
Concert Pharmaceuticals
Treatments:
Ivacaftor